p = n.s.) but higher (p < 0.001) than projected adult height (Ranke, ProjAH; 148.2 ± 5.5 vs. 145.2 ± 6.7 cm; p = 0.001). Total height gain over ProjAH was 4.3 ± 4.6 cm (GH start early) and 5.8 ± 4.7 cm (GH start late, p = 0.021), respectively. Conclusions: GH may improve AH in UTS patients even when started late. The individual growth response could be estimated by the descriptive Model PredAH independent of age at treatment start.
Introduction
Growth hormone (GH) treatment improves growth and final height in short girls with Ullrich-Turner syndrome (UTS) [1] [2] [3] [4] . However, the response to GH is rather variable which may be explained by different treatment protocols such as dosing regimens, adjuvant therapy with oxandrolone, age at start of GH therapy and management of puberty. GH dose and age at initiation of GH treatment are among the most important factors for a beneficial outcome [5] . Management of puberty was also studied in de-tail. After starting estrogen treatment for the induction of puberty further height gain may be limited [5] [6] [7] , but other studies investigating the age at induction of puberty suggested different results [8, 9] . The actual therapeutic guidelines [10] recommend an early initiation of GH treatment after the age of 2 years as soon as the height of a patient with UTS falls below the third percentile of the growth chart for healthy females. The treatment with estrogens for the induction of puberty is recommended to be started at 12 years, but not later than 15 years, in order to avoid a delay in pubertal development [11, 12] .
There are still some girls with UTS who are diagnosed late and are presented to the pediatric endocrinologist in adolescence, when the effectiveness and individual responsiveness of GH treatment are a matter of debate [13, 14] . Up to now there are no strategies to manage growth and puberty in older patients with UTS. Therefore, we analyzed retrospectively adult height (AH) and predicted adult height (Model PredAH) in German UTS patients documented in the KIGS database after early and late GH treatment start.
Patients and Methods
German girls with UTS who were documented in the pharmacoepidemiological survey KIGS were extracted from the database for further analyses. KIGS is an international registry developed with the primary objective to record long-term efficacy and safety of recombinant human GH, Genotropin ® (Pfizer Inc., New York, N.Y., USA). KIGS is conducted in accordance with the Declaration of Helsinki [15] . 313 UTS patients from 96 German centers who reached AH (bone ages >14 years according to Greulich and Pyle (GP) [16] and/or height velocities <2 cm/year at their latest visits) were identified. The patients were grouped according to their chronological ages at GH treatment start: before (n = 259) and equal or after (n = 54) 12 years of age. This cut-off was deduced from prior analyses of the mean chronological age at the start of puberty for the normal female population (11.2 ± 1.1 years) [17] . The diagnoses of UTS were confirmed by karyotype analyses as listed in table 1 .
Anthropometric data were extracted from the KIGS database: birth lengths (cm), birth weights (g), parental heights (cm) and heights (cm), weights (kg) and bone ages at start of GH therapy, at start of puberty and at last visits (AH). Percentiles and standard deviation scores (SDS) were extrapolated based on specific references by Niklasson et al. [18] for birth weights and birth lengths, by Freeman et al. [19] for weight and BMI, by Ranke et al. [20] for UTS-specific heights and by Reinken and van Oost [22] for normal heights. AH SDS were calculated based on adult UTS references [20] and on normal adult references [21] . Puberty onset was defined as the first time of reported breast stage ≥ B2 or the time when estrogen replacement started.
At GH start, projected adult heights (Ranke, ProjAH) [20] , prospective final heights (Bayley-Pinneau, BP) [22] and predicted heights (descriptive KIGS model of Ranke, Model PredAH) [23] were calculated and compared to AH (cm and syndrome-specific SDS). ProjAH was calculated assuming that in untreated patients with UTS the spontaneous disease-specific AH SDS corresponds to the disease-specific height SDS at presentation [20] , prospective final height (BP) was calculated based on the bone age rating (GP) at GH start [22] and Model PredAH was calculated utilizing the descriptive model for Turner patients treated with GH [23] .
Model PredAH -based on the descriptive model of Ranke et al. [23] -includes the prediction of the first year on GH and was calculated as follows: AH (cm) = 142.9 + (MPH SDS × 1. [23, 24] . Pubertal growth was analyzed in terms of observed and predicted total pubertal growth (TPG) as described previously [25] . Total height gains were calculated as the differences between AH and ProjAH.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analysis was performed by Wilcoxon and Fisher tests and χ2 test. The results were considered significant at p < 0.05. SAS ® version 8 for Sun Solarix (SAS Institute, Cary, N.C., USA) was used for all statistical analyses.
Results
The relative frequency of documented karyotypes was not different between patients with early and late start of GH treatment ( table 1 ) . Modalities of GH treatment are depicted in table 2 . While GH doses and frequencies were comparable in the two treatment groups, duration of treatment was significantly shorter in the late-start GH treatment group. The auxological characteristics of all patients at birth, at the time of GH start, after 1 year of GH treatment, at start of puberty and at AH are outlined in table 3 .
While birth weights and birth lengths were similar in early and late GH-treated patients, parental heights were significantly higher in early treated patients ( table 3 ) .
At GH start, chronological ages and bone ages were significantly different in the two groups as were heights. Bone ages were more retarded compared to chronological ages in late GH-treated patients. BMI were comparable at GH start in early and late treated patients. ProjAH and BP were similar in the patients groups but higher in early treated patients. Model PredAH were comparable in the two groups but higher than ProjAH and BP ( table 3 ) .
Heights of all patients improved after 1 year of GH treatment and thereafter until start of puberty and further to AH ( table 3 ; fig. 1 ).
At start of puberty, patients of the late treatment start group were significantly older than early treated patients whereas bone ages and heights (cm) were similar ( table 3 ; fig. 1 ). Puberty was induced with estrogens in 72.2% (early GH start) and 83.3% (late GH start) of the patients, respectively. Again, no differences in BMI were observed between the two groups at start of puberty ( table 3 ) .
AH were comparable in both treatment groups and similar to Model PredAH which were greater than ProjAH ( fig. 2 ). The total height gain over ProjAH was 4.3 ± 4.6 cm in early GH-treated patients and 5.8 ± 4.7 cm in late GH-treated patients (p ≤ 0.021) ( table 3 ) . At AH, late treated patients were significantly older than early treated patients, but no difference between their bone ages was noticed.
Height velocities (cm/year) during the first treatment year were significantly higher in early treated patients compared to late treated patients whereas TPG (cm) were similar in the two groups ( table 3 ) . However, observed TPG was higher than expected in the late treated group. BMI SDS slightly increased during GH treatment to a similar extent in both groups ( table 3 ) .
Discussion
In this retrospective study, German UTS patients documented in the KIGS database who had reached AH after GH treatment were analyzed dependent on the age at start of GH treatment in order to evaluate the efficacy of late GH treatment start in adolescence and to assess the significance of a prediction model in selecting GH-responsive patients at early and late treatment start.
GH treatment in UTS girls aims at early catch-up growth in childhood, at near normalization of height before puberty and finally at an increase of AH. Current guidelines for GH treatment of short stature in UTS recommend a treatment start at an early age as soon as the height falls below the third percentile of the specific reference growth chart and to initiate treatment with estrogens between the chronological ages of 12-13 years [10, 12] . However, more than 20% of UTS patients are diagnosed beyond the age of 11 years, most of them with a serious height deficit and delayed or arrested puberty [13, 14] . These patients have then missed the opportunity of early GH treatment and failed the option of normalization of height during childhood and of age-appropriate induction of puberty. The age at initiation of GH treatment as well as the age and the height at puberty onset and duration of GH treatment are important prognostic factors for final height in UTS [5, 9, 10, [26] [27] [28] . Our present study as well as a previous report on late GH therapy in UTS girls analyzing first-year height velocities (n = Table 2 . Modalities of GH therapy in the patients (n = 313) grouped by the age at treatment start (early, n = 259 and late, n = 54); variables are presented as mean ± SD 360 345) and near AHs (n = 28) from KIGS clearly indicate that late initiation of GH therapy shows robust height improvement [29] disproving a preceding single center study which reported no further height gains after puberty onset in 42 UTS patients [5] . The appropriate age to induce puberty in UTS patients remains a matter of debate [8, 30, 31] . Initiation of GH treatment early allows timely estrogen supplementation and prevents further height loss in childhood and adolescence and therefore might reduce the psychological harm of short stature and hypogonadism [33, 34] . This goal can be reached when UTS patients are diagnosed and treated with GH early, e.g. before 12 years of age [34] . Some reports suggested that even low estrogens levels lead to skeletal maturation and compromise final height, but delayed administration of estrogens prolongs growth before puberty [36] [37] [38] . In our present study, estrogen therapy was started in the late GH treatment group at a mean age of 15.4 years compared to 13.3 years in the early treatment group and observed TPG was similar as in early treated patients which may explain why late treated patients had more total height gain than early treated patients resulting in similar AH (152.5 vs. 151.1 cm). This is in accordance with previous reports, which revealed a beneficial effect of GH treatment even during late estrogen supplementation in UTS patients [39, 40] . In contrast, low-dose estrogens alone failed to improve final heights in UTS patients [41, 42] . Therefore, late GH treatment start seems to be justified in UTS patients and appropriate tools such as prediction models should be identified to estimate individual responsiveness before start of GH treatment in order to quantify treatment expectations of patients, physicians and healthcare providers. Several models were reported to predict the effect of GH treatment [23, 32] . The prediction of growth responses in these models is based mainly on auxological and endocrine parameters [23, 32] . GH dose was the most important predictor for height velocity in the first year of GH treatment in UTS patients. Thereafter, the height velocity in the previous year is the most important predictor of the final outcome [23, 24] . Based on this model it was suggested that the individual first-year response determines the AH most. In our study, first-year height velocities of early treated patients were higher than first-year height velocities of late treated patients. We evaluated retrospectively Model PredAH as a tool to select GH-responsive patients at GH treatment start. AH varied considerably but were similar in all patients treated with GH, independent of age at treatment start, and significantly above the average AH for German UTS references and ProjAH [20] . The variability of AH indicate that UTS patients in fact respond differently to GH treatment. In both groups the descriptive model predicted a very similar AH at start of treatment despite the fact that patients who were treated late were significantly older at start of treatment, at start of puberty and at AH in comparison to the group used for model development. Apart from that, bone ages and heights (cm) at start of puberty were similar in both groups. These results and others indicate that Model PredAH can represent a reliable tool to identify GH-responsive UTS patients irrespective of their age at start of GH therapy [23, 24] .
In summary, this retrospective study provides strong evidence that late start of GH treatment in adolescence may still improve final heights in short girls with UTS above ProjAH. However, this regimen implies perpetuation of short stature in childhood and significant delay of pubertal development. Therefore, GH treatment start should not be delayed until adolescence. However, our results indicate that adolescent UTS patients with short stature should not be excluded a priori from GH treatment. Model PredAH can estimate GH-stimulated growth in UTS patients before and in the course of adolescence and may therefore represent a tool to estimate individual responsiveness before start of GH treatment in order to quantify treatment expectations of patients, physicians and healthcare providers even when their diagnosis was missed in childhood.
